Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Research

Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome

Authors: Xiaoyuan Wei, Yu Min, Ge Song, Xin Ye, Lei Liu

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Triglyceride-glucose (TyG) index has been determined to play a role in the onset of metabolic syndrome (MetS). Whether the TyG index and TyG with the combination of obesity indicators are associated with the clinical outcomes of the MetS population remains unknown.

Method

Participants were extracted from multiple cycles of the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2018 years. Three indicators were constructed including TyG index, TyG combining with waist circumference (TyG-WC), and TyG combining with waist-to-height ratio (TyG-WHtR). The MetS was defined according to the National Cholesterol Education Program (NCPE) Adult Treatment Panel III. Kaplan-Meier (KM) curves, restricted cubic splines (RCS), and the Cox proportional hazard model were used to evaluate the associations between TyG-related indices and mortality of the MetS population. The sensitive analyses were performed to check the robustness of the main findings.

Results

There were 10,734 participants with MetS included in this study, with 5,570 females and 5,164 males. The median age of the study population was 59 years old. The multivariate Cox regression analyses showed high levels of TyG-related indices were significantly associated with the all-cause mortality of MetS population [TyG index: adjustedhazard ratio (aHR): 1.36, 95%confidence interval (CI): 1.18–1.56, p < 0.001; TyG-WHtR index: aHR = 1.29, 95%CI: 1.13–1.47, p < 0.001]. Meanwhile, the TyG-WC and TyG-WHtR index were associated with cardiovascular mortality of the MetS population (TyG-WC: aHR = 1.45, 95%CI: 1.13–1.85, p = 0.004; TyG-WHtR: aHR = 1.50 95%CI: 1.17–1.92, p = 0.002). Three TyG-related indices showed consistent significant correlations with diabetes mortality (TyG: aHR = 4.06, 95%CI: 2.81–5.87, p < 0.001; TyG-WC: aHR = 2.55, 95%CI: 1.82–3.58, p < 0.001; TyG-WHtR: aHR = 2.53 95%CI: 1.81–3.54, p < 0.001). The RCS curves showed a non-linear trend between TyG and TyG-WC indices with all-cause mortality (p for nonlinearity = 0.004 and 0.001, respectively). The sensitive analyses supported the positive correlations between TyG-related indices with mortality of the MetS population.

Conclusion

Our study highlights the clinical value of TyG-related indices in predicting the survival of the MetS population. TyG-related indices would be the surrogate biomarkers for the follow-up of the MetS population.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010. J Am Coll Cardiol. 2013;62(8):697–703.PubMedPubMedCentralCrossRef
5.
Shin D, Kongpakpaisarn K, Bohra C. Trends in the prevalence of metabolic syndrome and its components in the United States 2007–2014. Int J Cardiol. 2018;259:216–9.PubMedCrossRef
6.
Li W, Qiu X, Ma H, Geng Q. Incidence and long-term specific mortality trends of metabolic syndrome in the United States. Front Endocrinol. 2022;13:1029736.CrossRef
7.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113–32.PubMedCrossRef
8.
9.
Li W, Chen D, Peng Y, Lu Z, Kwan MP, Tse LA. Association between metabolic syndrome and mortality: prospective cohort study. JMIR Public Health Surveillance. 2023;9:e44073.PubMedPubMedCentralCrossRef
10.
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022;23(2).
11.
Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metabolic Syndrome. 2022;16(8):102581.PubMedCrossRef
12.
Tao LC, Xu JN, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.PubMedPubMedCentralCrossRef
13.
Mirr M, Skrypnik D, Bogdański P, Owecki M. Newly proposed insulin resistance indexes called TyG-NC and TyG-NHtR show efficacy in diagnosing the metabolic syndrome. J Endocrinol Investig. 2021;44(12):2831–43.CrossRef
14.
Son DH, Lee HS, Lee YJ, Lee JH, Han JH. Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2022;32(3):596–604.PubMed
15.
Li Y, Zheng R, Li S, Cai R, Ni F, Zheng H, et al. Association between four anthropometric indexes and metabolic syndrome in US adults. Front Endocrinol. 2022;13:889785.CrossRef
16.
Kang SW, Kim SK, Kim YS, Park MS. Risk prediction of the metabolic syndrome using TyG index and SNPs: a 10-year longitudinal prospective cohort study. Mol Cell Biochem. 2023;478(1):39–45.PubMedCrossRef
17.
Primo D, Izaola O, de Luis DA. Triglyceride-glucose index cutoff point is an accurate marker for Predicting the prevalence of metabolic syndrome in obese caucasian subjects. Ann Nutr Metab. 2023;79(2):70–7.CrossRef
18.
Li Y, Gui J, Liu H, Guo LL, Li J, Lei Y, et al. Predicting metabolic syndrome by obesity- and lipid-related indices in mid-aged and elderly Chinese: a population-based cross-sectional study. Front Endocrinol. 2023;14:1201132.CrossRef
19.
Nabipoorashrafi SA, Seyedi SA, Rabizadeh S, Ebrahimi M, Ranjbar SA, Reyhan SK, et al. The accuracy of triglyceride-glucose (TyG) index for the screening of metabolic syndrome in adults: a systematic review and meta-analysis. Nutrition, metabolism, and cardiovascular diseases. NMCD. 2022;32(12):2677–88.PubMed
20.
Liao Y, Zhang R, Shi S, Zhao Y, He Y, Liao L, et al. Triglyceride-glucose index linked to all-cause mortality in critically ill patients: a cohort of 3026 patients. Cardiovasc Diabetol. 2022;21(1):128.PubMedPubMedCentralCrossRef
21.
Boshen Y, Yuankang Z, Xinjie Z, Taixi L, Kaifan N, Zhixiang W, et al. Triglyceride-glucose index is associated with the occurrence and prognosis of cardiac arrest: a multicenter retrospective observational study. Cardiovasc Diabetol. 2023;22(1):190.PubMedPubMedCentralCrossRef
22.
Liang S, Wang C, Zhang J, Liu Z, Bai Y, Chen Z, et al. Triglyceride-glucose index and coronary artery disease: a systematic review and meta-analysis of risk, severity, and prognosis. Cardiovasc Diabetol. 2023;22(1):170.PubMedPubMedCentralCrossRef
23.
Zhou Y, Wang C, Che H, Cheng L, Zhu D, Rao C, et al. Association between the triglyceride-glucose index and the risk of mortality among patients with chronic heart failure: results from a retrospective cohort study in China. Cardiovasc Diabetol. 2023;22(1):171.PubMedPubMedCentralCrossRef
24.
Kityo A, Lee SA. Association of cardiometabolic factors and insulin resistance surrogates with mortality in participants from the Korean Genome and Epidemiology Study. Lipids Health Dis. 2023;22(1):210.PubMedPubMedCentralCrossRef
25.
Dang K, Wang X, Hu J, Zhang Y, Cheng L, Qi X, et al. The association between triglyceride-glucose index and its combination with obesity indicators and cardiovascular disease: NHANES 2003–2018. Cardiovasc Diabetol. 2024;23(1):8.PubMedPubMedCentralCrossRef
26.
Er LK, Wu S, Chou HH, Hsu LA, Teng MS, Sun YC, et al. Triglyceride glucose-body Mass Index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS ONE. 2016;11(3):e0149731.PubMedPubMedCentralCrossRef
27.
Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National health and nutrition examination survey: sample design, 2011–2014. Vital and health statistics Series 2, Data evaluation and methods research. 2014(162):1–33.
28.
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.CrossRef
29.
Ding Z, Ge M, Tan Y, Chen C, Hei Z. The triglyceride-glucose index: a novel predictor of stroke and all-cause mortality in liver transplantation recipients. Cardiovasc Diabetol. 2024;23(1):27.PubMedPubMedCentralCrossRef
30.
Yan F, Yan S, Wang J, Cui Y, Chen F, Fang F, et al. Association between triglyceride glucose index and risk of cerebrovascular disease: systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):226.PubMedPubMedCentralCrossRef
31.
Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Reviews: Official J Int Association Study Obes. 2012;13(3):275–86.CrossRef
32.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299–304.PubMedCrossRef
33.
Zheng S, Shi S, Ren X, Han T, Li Y, Chen Y, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. J Translational Med. 2016;14(1):260.CrossRef
34.
Lim J, Kim J, Koo SH, Kwon GC. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: an analysis of the 2007–2010 Korean National Health and Nutrition Examination Survey. PLoS ONE. 2019;14(3):e0212963.PubMedPubMedCentralCrossRef
35.
Cao C, Cade WT, Li S, McMillan J, Friedenreich C, Yang L. Association of balance function with all-cause and cause-Specific Mortality among US adults. JAMA otolaryngology– head neck Surg. 2021;147(5):460–8.CrossRef
36.
Abha P, Keshari JR, Sinha SR, Nishant K, Kumari R, Prakash P. Association of thyroid function with lipid Profile in patients with metabolic syndrome: a prospective cross-sectional study in the Indian Population. Cureus. 2023;15(9):e44745.PubMedPubMedCentral
37.
Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ (Clinical Res ed). 1995;310(6973):170.CrossRef
38.
Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome - what is it and how should it be managed? Eur J Prev Cardiol. 2019;26(2suppl):33–46.PubMedCrossRef
39.
Duan Y, Zhang W, Li Z, Niu Y, Chen Y, Liu X, et al. Predictive ability of obesity- and lipid-related indicators for metabolic syndrome in relatively healthy Chinese adults. Front Endocrinol. 2022;13:1016581.CrossRef
40.
Zheng R, Qian S, Shi Y, Lou C, Xu H, Pan J. Association between triglyceride-glucose index and in-hospital mortality in critically ill patients with sepsis: analysis of the MIMIC-IV database. Cardiovasc Diabetol. 2023;22(1):307.PubMedPubMedCentralCrossRef
41.
Huang R, Xu X, Xu C, Zhang S, Xiong Z, Liu M, et al. Association between the insulin resistance and all-cause mortality in patients with moderate and severe aortic stenosis: a retrospective cohort study. Cardiovasc Diabetol. 2023;22(1):238.PubMedPubMedCentralCrossRef
42.
Ren H, Yang Y, Wang F, Yan Y, Shi X, Dong K, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol. 2020;19(1):58.PubMedPubMedCentralCrossRef
43.
Zhang R, Shi S, Chen W, Wang Y, Lin X, Zhao Y, et al. Independent effects of the triglyceride-glucose index on all-cause mortality in critically ill patients with coronary heart disease: analysis of the MIMIC-III database. Cardiovasc Diabetol. 2023;22(1):10.PubMedPubMedCentralCrossRef
44.
Antonopoulos AS, Oikonomou EK, Antoniades C, Tousoulis D. From the BMI paradox to the obesity paradox: the obesity-mortality association in coronary heart disease. Obes Reviews: Official J Int Association Study Obes. 2016;17(10):989–1000.CrossRef
45.
Strulov Shachar S, Williams GR. The obesity Paradox in Cancer-moving beyond BMI. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Cosponsored Am Soc Prev Oncol. 2017;26(1):13–6.
46.
47.
48.
Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies. BMJ (Clinical Res ed). 2020;370:m3324.
49.
Ramírez-Manent JI, Jover AM, Martinez CS, Tomás-Gil P, Martí-Lliteras P, López-González. Á A. Waist circumference is an essential factor in Predicting insulin resistance and early detection of metabolic syndrome in adults. Nutrients. 2023;15(2).
50.
Kawada T, Andou T, Fukumitsu M. Waist circumference, visceral abdominal fat thickness and three components of metabolic syndrome. Diabetes Metabolic Syndrome. 2016;10(1):4–6.PubMedCrossRef
51.
Claypool K, Long MT, Patel CJ. Waist circumference and insulin resistance are the most predictive metabolic factors for steatosis and fibrosis. Clin Gastroenterol Hepatology: Official Clin Pract J Am Gastroenterological Association. 2023;21(7):1950–e41.CrossRef
52.
Xia B, He Q, Pan Y, Gao F, Liu A, Tang Y, et al. Metabolic syndrome and risk of pancreatic cancer: a population-based prospective cohort study. Int J Cancer. 2020;147(12):3384–93.PubMedCrossRef
53.
Wu CJ, Kao TW, Chen YY, Yang HF, Chen WL. Peripheral fat distribution versus waist circumference for predicting mortality in metabolic syndrome. Diab/Metab Res Rev. 2019;35(4):e3116.CrossRef
54.
Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care. 2006;29(2):404–9.PubMedCrossRef
55.
Xiao X, Yu X, Zhu H, Zhai X, Li S, Ma W et al. Arm circumference, arm-to-Waist ratio in relation to Cardiovascular and all-cause mortality among patients with diabetes Mellitus. Nutrients. 2023;15(4).
56.
Yuan Y, Liu K, Zheng M, Chen S, Wang H, Jiang Q, et al. Analysis of changes in Weight, Waist circumference, or both, and all-cause mortality in Chinese adults. JAMA Netw open. 2022;5(8):e2225876.PubMedPubMedCentralCrossRef
57.
Lo K, Huang YQ, Shen G, Huang JY, Liu L, Yu YL, et al. Effects of waist to height ratio, waist circumference, body mass index on the risk of chronic diseases, all-cause, cardiovascular and cancer mortality. Postgrad Med J. 2021;97(1147):306–11.PubMedCrossRef
58.
Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab. 2010;95(4):1777–85.PubMedCrossRef
59.
Parente EB, Mutter S, Harjutsalo V, Ahola AJ, Forsblom C, Groop PH. Waist-height ratio and waist are the best estimators of visceral fat in type 1 diabetes. Sci Rep. 2020;10(1):18575.PubMedPubMedCentralCrossRef
60.
61.
Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–46.PubMedCrossRef
62.
Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metabol. 2012;15(5):635–45.CrossRef
Metadata
Title
Association between triglyceride-glucose related indices with the all-cause and cause-specific mortality among the population with metabolic syndrome
Authors
Xiaoyuan Wei
Yu Min
Ge Song
Xin Ye
Lei Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02215-0

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue

Research

Multiplexed MRM-based proteomics for identification of circulating proteins as biomarkers of cardiovascular damage progression associated with diabetes mellitus

Research

Circulating palmitoyl sphingomyelin levels predict the 10-year increased risk of cardiovascular disease death in Chinese adults: findings from the Da Qing Diabetes Study

Comment

The skin autofluorescence may help to select patients with Type 2 diabetes candidates for screening to revascularization procedures

Research

Factors influencing hospitalization or emergency department visits and mortality in type 2 diabetes following the onset of new cardiovascular diagnoses in a population-based study

Research

The association between the AIP and undiagnosed diabetes in ACS patients with different body mass indexes and LDL-C levels: findings from the CCC-ACS project

Correction

Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits